Read More Pharma Industry News Takeda’s NINLARO fails to meet PFS primary endpoint in TOURMALINE-MM2 trial Takeda Pharmaceutical said that the Phase 3 TOURMALINE-MM2 trial in newly diagnosed multiple myeloma patients for NINLARO (ixazomib)… bypharmanewsdailySeptember 11, 2020
